Erratum: MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes (American Society for Clinical Investigation (2014) 124:10 (4305-4319) DOI: 10.1172/JCI77116);MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes

Journal of Clinical Investigation

Volumn 124, Issue 10, 2014, Pages 4305-4319

  Sachdeva, Mohit ^a   Mito, Jeffrey K ^a,g   Lee, Chang Lung ^a   Zhang, Minsi ^a   Li, Zhizhong ^a,h   Dodd, Rebecca D ^a   Cason, David ^a   Luo, Lixia ^a   Ma, Yan ^a   Van Mater, David ^a   Gladdy, Rebecca ^b,c,d   Lev, Dina C ^e   Cardona, Diana M ^f   Kirsch, David G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Department of Surgery ^*  (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

^e UNIVERSITY OF TEXAS   (United States)

^f DUKE UNIVERSITY   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 182; MICRORNA; MIRN182 MICRORNA, HUMAN; MIRN182 MICRORNA, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MIGRATION; CIRCULATING TUMOR CELL; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; GENE OVEREXPRESSION; GENE TARGETING; GENETIC REGULATION; GENETICALLY ENGINEERED MOUSE STRAIN; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MALE; METASTASIS; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIMARY TUMOR; PROTEOMICS; SARCOMA; SARCOMA CELL; SOFT TISSUE SARCOMA; ALLELE; ANIMAL; CELL MOTION; GENE DELETION; GENETIC ENGINEERING; GENETICS; LUNG TUMOR; METABOLISM; NUDE MOUSE; SOFT TISSUE TUMOR; TRANSGENIC MOUSE; TUMOR CELL LINE; TUMOR EMBOLISM;

ALLELES; ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; EXTRACELLULAR MATRIX; GENE DELETION; GENETIC ENGINEERING; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; MICE, TRANSGENIC; MICRORNAS; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 84907495479     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI86573     Document Type: Erratum

References (77)

1. Lyman GH, Djulbegovic B. The challenge of systematic reviews of diagnostic and staging studies in cancer. Cancer Treat Rev. 2005;31(8):628-639.
2. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9(4):274-284.
3. Ambros V. microRNAs: tiny regulators with great potential. Cell. 2001;107(7):823-826.
4. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-297.
5. White NM, Fatoohi E, Metias M, Jung K, Stephan C, Yousef GM. Metastamirs: a stepping stone towards improved cancer management. Nat Rev Clin Oncol. 2011;8(2):75-84.
6. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449(7163):682-688.
7. Sachdeva M, Mo YY. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res. 2010;70(1):378-387.
8. Tavazoie SF, et al. Endogenous human micro-RNAs that suppress breast cancer metastasis. Nature. 2008;451(7175):147-152.
9. Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo YY. Micro-RNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 2008;18(3):350-359.
10. Kirsch DG, et al. A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med. 2007;13(8):992-997.
11. Mito JK, et al. Oncogene-dependent control of miRNA biogenesis and metastatic progression in a model of undifferentiated pleomorphic sarcoma. J Pathol. 2013;229(1):132-140.
12. Segura MF, et al. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci U S A. 2009;106(6):1814-1819.
13. Larramendy ML, et al. Comparative genomic hybridization of malignant fibrous histiocytoma reveals a novel prognostic marker. Am J Pathol. 1997;151(4):1153-1161.
14. Parente F, Grosgeorge J, Coindre JM, Terrier P, Vilain O, Turc-Carel C. Comparative genomic hybridization reveals novel chromosome deletions in 90 primary soft tissue tumors. Cancer Genet Cytogenet. 1999;115(2):89-95.
15. Calin GA, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004;101(9):2999-3004.
16. Alix-Panabieres C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem. 2013;59(1):110-118.
17. Satelli A, et al. Universal marker and detection tool for human sarcoma circulating tumor cells. Cancer Res. 2014;74(6):1645-1650.
18. Qiu Y, et al. TGF-β upregulates miR-182 expression to promote gallbladder cancer metastasis by targeting CADM1. Mol Biosyst. 2014;10(3):679-685.
19. Lei R, et al. Suppression of MIM by microRNA-182 activates RhoA and promotes breast cancer metastasis. Oncogene. 2014;33(10):1287-1296.
20. Didiano D, Hobert O. Perfect seed pairing is not a generally reliable predictor for miRNA-target interactions. Nat Struct Mol Biol. 2006;13(9):849-851.
21. Dougherty GW, Jose C, Gimona M, Cutler ML. The Rsu-1-PINCH1-ILK complex is regulated by Ras activation in tumor cells. Eur J Cell Biol. 2008;87(8):721-734.
22. Wang D, Xu MR, Wang T, Li T, Zhu J. MTSS1 overexpression correlates with poor prognosis in colorectal cancer. J Gastrointest Surg. 2011;15(7):1205-1212.
23. Ulisse S, Baldini E, Sorrenti S, D'Armiento M. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets. 2009;9(1):32-71.
24. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta. 2000;1477(1):267-283.
25. Jiang L, et al. miR-182 as a prognostic marker for glioma progression and patient survival. Am J Pathol. 2010;177(1):29-38.
26. Dettmer M, et al. MicroRNA expression array identifies novel diagnostic markers for conventional and oncocytic follicular thyroid carcinomas. J Clin Endocrinol Metab. 2013;98(1):E1-E7.
27. Pignot G, et al. microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer. Int J Cancer. 2013;132(11):2479-2491.
28. Tsuchiyama K, et al. Expression of MicroRNAs associated with Gleason grading system in prostate cancer: miR-182-5p is a useful marker for high grade prostate cancer. Prostate. 2013;73(8):827-834.
29. Ghossein RA, Bhattacharya S, Rosai J. Molecular detection of micrometastases and circulating tumor cells in solid tumors. Clin Cancer Res. 1999;5(8):1950-1960.
30. Ghossein RA, Bhattacharya S. Molecular detection and characterization of circulating tumor cells and micrometastases in prostatic, urothelial, and renal cell carcinomas. Semin Surg Oncol. 2001;20(4):304-311.
31. Mocellin S, et al. Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma. Int J Cancer. 2004;111(5):741-745.
32. Cristofanilli M, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351(8):781-791.
33. Cohen SJ, et al. Relationship of circulating tumor cells to tumor response, progressionfree survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(19):3213-3221.
34. De Bono JS, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14(19):6302-6309.
35. Moreno JG, et al. Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status. Urology. 2001;58(3):386-392.
36. Eliane JP, et al. Monitoring serial changes in circulating human breast cancer cells in murine xenograft models. Cancer Res. 2008;68(14):5529-5532.
37. Rhim AD, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148(1):349-361.
38. Lei R, et al. Suppression of MIM by microRNA-182 activates RhoA and promotes breast cancer metastasis. Oncogene. 2014;33(10):1287-1296.
39. Wang YQ, Guo RD, Guo RM, Sheng W, Yin LR. MicroRNA-182 promotes cell growth, invasion, and chemoresistance by targeting programmed cell death 4 (PDCD4) in human ovarian carcinomas. J Cell Biochem. 2013;114(7):1464-1473.
40. Cubellis MV, Wun TC, Blasi F. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J. 1990;9(4):1079-1085.
41. Ellis V, Wun TC, Behrendt N, Ronne E, Dano K. Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. J Biol Chem. 1990;265(17):9904-9908.
42. Fisher JL, Mackie PS, Howard ML, Zhou H, Choong PF. The expression of the urokinase plasminogen activator system in metastatic murine osteosarcoma: an in vivo mouse model. Clin Cancer Res. 2001;7(6):1654-1660.
43. Kramer MD, Reinartz J, Brunner G, Schirrmacher V. Plasmin in pericellular proteolysis and cellular invasion. Invasion Metastasis. 1994;14(1):210-222.
44. Setyono-Han B, et al. Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1. Thromb Haemost. 2005;93(4):779-786.
45. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev. 2003;22(2):205-222.
46. Henneke I, et al. Inhibition of urokinase activity reduces primary tumor growth and metastasis formation in a murine lung carcinoma model. Am J Respir Crit Care Med. 2010;181(6):611-619.
47. Kotzsch M, et al. Combined mRNA expression levels of members of the urokinase plasminogen activator (uPA) system correlate with diseaseassociated survival of soft-tissue sarcoma patients. BMC Cancer. 2011;11:273.
48. Vial D, McKeown-Longo PJ. PAI1 stimulates assembly of the fibronectin matrix in osteosarcoma cells through crosstalk between the αvβ5 and α5β1 integrins. J Cell Sci. 2008;121(pt 10):1661-1670.
49. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol. 1997;74(2):111-122.
50. Yasumitsu H, Wakabayashi E, Kitajima H, Sakamoto Y, Miyazaki K. [TIMPs (tissue inhibitors of metalloproteinases): their species, functions and effects on tumor metastasis]. Nihon Rinsho. 1995;53(7):1798-1804.
51. Miyagi E, et al. Characterization of matrixdegrading proteinases and their inhibitors secreted by human gynecological carcinoma cells. Jpn J Cancer Res. 1995;86(6):568-576.
52. Wang N, Zhu M, Tsao SW, Man K, Zhang Z, Feng Y. Up-regulation of TIMP-1 by genipin inhibits MMP-2 activities and suppresses the metastatic potential of human hepatocellular carcinoma. PLoS One. 2012;7(9):e46318.
53. Tanaka K, et al. Cyclic AMP-regulated synthesis of the tissue inhibitors of metalloproteinases suppresses the invasive potential of the human fibrosarcoma cell line HT1080. Cancer Res. 1995;55(13):2927-2935.
54. Xin ZF, Shen CC, Tao LJ, Yan SG, Wu HB. Gambogic acid inhibits invasion of osteosarcoma via upregulation of TIMP-1. Int J Mol Med. 2013;31(1):105-112.
55. Benassi MS, et al. Tissue and serum loss of metalloproteinase inhibitors in high grade soft tissue sarcomas. Histol Histopathol. 2003;18(4):1035-1040.
56. Cutler ML, Bassin RH, Zanoni L, Talbot N. Isolation of rsp-1, a novel cDNA capable of suppressing v-Ras transformation. Mol Cell Biol. 1992;12(9):3750-3756.
57. Vasaturo F, Dougherty GW, Cutler ML. Ectopic expression of Rsu-1 results in elevation of p21CIP and inhibits anchorage-independent growth of MCF7 breast cancer cells. Breast Cancer Res Treat. 2000;61(1):69-78.
58. Dougherty GW, Chopp T, Qi SM, Cutler ML. The Ras suppressor Rsu-1 binds to the LIM 5 domain of the adaptor protein PINCH1 and participates in adhesion-related functions. Exp Cell Res. 2005;306(1):168-179.
59. Machesky LM, Johnston SA. MIM: a multifunctional scaffold protein. J Mol Med. 2007;85(6):569-576.
60. Lee YG, Macoska JA, Korenchuk S, Pienta KJ. MIM, a potential metastasis suppressor gene in bladder cancer. Neoplasia. 2002;4(4):291-294.
61. Millard TH, Dawson J, Machesky LM. Characterisation of IRTKS, a novel IRSp53/MIM family actin regulator with distinct filament bundling properties. J Cell Sci. 2007;120(pt 9):1663-1672.
62. Dawson JC, Bruche S, Spence HJ, Braga VM, Machesky LM. Mtss1 promotes cell-cell junction assembly and stability through the small GTPase Rac1. PLoS One. 2012;7(3):e31141.
63. Callahan CA, et al. MIM/BEG4, a Sonic hedgehogresponsive gene that potentiates Gli-dependent transcription. Genes Dev. 2004;18(22):2724-2729.
64. Liu K, Wang G, Ding H, Chen Y, Yu G, Wang J. Downregulation of metastasis suppressor 1 (MTSS1) is associated with nodal metastasis and poor outcome in Chinese patients with gastric cancer. BMC Cancer. 2010;10:428.
65. Parr C, Jiang WG. Metastasis suppressor 1 (MTSS1) demonstrates prognostic value and anti-metastatic properties in breast cancer. Eur J Cancer. 2009;45(9):1673-1683.
66. Wang J, Li J, Shen J, Wang C, Yang L, Zhang X. MicroRNA-182 downregulates metastasis suppressor 1 and contributes to metastasis of hepatocellular carcinoma. BMC Cancer. 2012;12:227.
67. Jackson EL, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 2001;15(24):3243-3248.
68. Jonkers J, Meuwissen R, Van der Gulden H, Peterse H, Van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet. 2001;29(4):418-425.
69. Witten DM, Tibshirani R. A framework for feature selection in clustering. J Am Stat Assoc. 2010;105(490):713-726.
70. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T)) Method. Methods. 2001;25(4):402-408.
71. Zhang Y, Buchholz F, Muyrers JP, Stewart AF. A new logic for DNA engineering using recombination in Escherichia coli. Nat Genet. 1998;20(2):123-128.
72. Datta S, Costantino N, Court DL. A set of recombineering plasmids for gram-negative bacteria. Gene. 2006;379:109-115.
73. Madisen L, et al. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat Neurosci. 2010;13(1):133-140.
74. Nagy A, Rossant J, Nagy R, Abramow-Newerly W, Roder JC. Derivation of completely cell culture-derived mice from early-passage embryonic stem cells. Proc Natl Acad Sci U S A. 1993;90(18):8424-8428.
75. Sachdeva M, et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci U S A. 2009;106(9):3207-3212.
76. Gilar M, Olivova P, Daly AE, Gebler JC. Two-dimensional separation of peptides using RP-RP-HPLC system with different pH in first and second separation dimensions. J Sep. Sci. 2005;28(14):1694-1703.
77. Gilar M, Olivova P, Daly AE, Gebler JC. Orthogonality of separation in two-dimensional liquid chromatography. Anal Chem. 2005;77(19):6426-6434.